- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Impel NeuroPharma and Veeva Collaborate on Market Preparation for Migraine Treatment
FDA accepted Impel’s new drug application (NDA) for TRUDHESA last month.
Impel NeuroPharma (Seattle, WA) and Veeva Systems have announced a strategic partnership to collaborate on pre-launch preparations for Impel’s migraine treatment INP104 which, if approved by FDA, will be marketed under the trade name TRUDHESA. TRUDHESA utilizes Impel’s proprietary Precision Olfactory Delivery (POD) technology to deliver treatment directly to the vascular-rich upper nasal space. Traditional nasal delivery systems, such as pumps or sprays, deliver medicine to the lower nasal cavity which can result in variability in efficacy because of unpredictable delivery and variable absorption into the bloodstream.
To accelerate its market preparation, Impel will adopt Veeva’s suite of commercial applications for in-person and digital engagement with physicians, for longitudinal patient data to segment right patients groups, and to design and implement customer-centric strategies to enable sales reps to increase the value of their targeted interactions.
“In January we were pleased that FDA accepted for review Impel’s new drug application (NDA) for TRUDHESA. Given this milestone, this is the perfect time for us to enter this strategic collaboration, as Veeva is a proven technology leader and the ideal partner to help us meet our aggressive commercial timelines,” said Adrian Adams, chairman and chief executive officer, Impel NeuroPharma. “We look forward to Veeva’s support and expertise to help us ensure an efficient, digital-first, and compliant approach to commercialization subject, of course, to approval by the FDA later this year.”
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?
October 15th 2024Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
